Prochlorperazine mesilate injection
- Drugs List
- Therapeutic Indications
- Precautions and Warnings
- Pregnancy and Lactation
- Side Effects
Solution for injection containing prochlorperazine mesilate
Schizophrenia and other psychoses
Treatment of nausea and vomiting
Treatment of nausea and vomiting
Initial dose: 12.5mg by deep intramuscular injection. Follow by oral medication after 6 hours if considered necessary.
Schizophrenia and other psychoses and acute mania
Initial dose: 12.5mg to 25mg two or three times a day by deep intramuscular injection until conversion to oral therapy is possible.
Use with caution, rate of metabolism and excretion of prochlorperazine decreases with age.
Consider a reduced dose based on adult dose.
Prochlorperazine injection is not licensed for use in children as it has been associated with dystonic reactions.
Treatment of nausea and vomiting (unlicensed)
Children aged 12 to 18 years
12.5mg by intramuscular injection, given up to three times a day, if necessary.
Children aged 5 to 12 years
5mg to 6.25mg by intramuscular injection, given up to three times a day, if necessary.
Children aged 2 to 5 years
1.25mg to 2.5mg by intramuscular injection, given up to three times a day, if necessary.
Patients with Renal Impairment
Prochlorperazine should be avoided in patients with renal dysfunction.
The Renal Drug Handbook recommends that patients with a glomerular filtration rate below 10 ml/minute be given small starting doses such as 5mg orally.
Children under 2 years
Central nervous system depression
Precautions and Warnings
Children aged 2 to 18 years
Predisposition to prolongation of QT interval
Benign prostatic hyperplasia
History of agranulocytosis
History of jaundice
History of narrow angle glaucoma
History of seizures
Organic brain syndrome
Severe respiratory disease
May mask symptoms of serious disease of the stomach and delay diagnosis
Advise impaired alertness may affect ability to drive or operate machinery
Not all available brands are licensed for all indications
Patients at risk of arrhythmias perform ECG prior to initiating therapy
Avoid contact of product with skin
Do not use if solution is discoloured or particulates are apparent
Local pain or nodule formation may occur after intramuscular administration
Diabetic control may need adjustment
Elderly more susceptible to sedation, hypotensive & temp regulatory effects
Examine eyes for defects in prolonged use
Monitor blood counts regularly
Monitor ECG in patients at risk of QT prolongation
Perform blood counts if unexplained infection or fever develops
May cause postural hypotension especially in elderly
May increase risk of seizure
May precipitate diabetes mellitus
Avoid abrupt withdrawal
Discontinue at first signs of jaundice
Discontinue if fever occurs
Discontinue if patient develops neuroleptic malignant syndrome
Reduce dose in elderly
Advise patient to avoid alcohol during treatment
Advise that effects are potentiated by CNS depressants (including alcohol)
Advise patient that photosensitivity possible
Advise patient to avoid exposure to direct sunlight
Prochlorperazine may potentiate QT prolongation which is exacerbated by the presence of bradycardia or hypokalaemia. Use with caution, monitoring biochemical status and ECG of patients with congenital or acquired predisposing factors for prolonged QT interval e.g. cardiac disease, alcohol abuse, starvation and other metabolic abnormalities such as hypokalaemia, hypocalcaemia or hypomagnesaemia, particularly during the initial phase of treatment.
Discontinue if jaundice occurs and use with caution in patients with a history of jaundice. A premonitory sign of an allergic hepato-biliary disorder manifesting as jaundice may be the sudden onset of fever after one to three weeks of treatment.
Discontinue if patient develops an unexplained fever as this may be a sign of neuroleptic malignant syndrome (pallor, hyperthermia, autonomic dysfunction, altered consciousness, muscle rigidity). Signs of autonomic dysfunction such as sweating and arterial instability may precede the onset of hyperthermia and serve as early warning signs. Use with caution in organic brain disease and volume depleted patients - increased risk of neuroleptic malignant syndrome.
Monitor full blood counts regularly. Agranulocytosis has been reported, occurrence of unexplained infections or fever may be evidence of blood dyscrasia and requires immediate haematological investigation.
There is an increased susceptibility to CNS side effects, postural hypotension, hypothermia, hyperthermia and drug-induced parkinsonism in the elderly particularly after prolonged use. Use with caution in the elderly and patients with Parkinson's disease. Care should be taken not to confuse the adverse effects of prochlorperazine e.g. orthostatic hypotension, with the effects due to the underlying disorder.
In schizophrenia response to prochlorperazine may be delayed. If treatment is withdrawn the recurrence of symptoms may not become apparent for some time.
Pregnancy and Lactation
Use prochlorperazine with caution in pregnancy.
Prochlorperazine crosses the placenta. According to Briggs and co-workers, short courses of low dose prochlorperazine may be considered as safe for both mother and foetus despite isolated reports of congenital defects in children who had been exposed to prochlorperazine in utero. UK licensed product information however, recommends that prochlorperazine should be avoided during pregnancy. Product information further mentions possible adverse effects on the neonate. These include lethargy or paradoxical hyperexcitability, tremor and low apgar scores.
Neuroleptics may occasionally prolong labour. It is then recommended that treatment is withheld until the cervix is dilated 3 to 4 cm.
When neuroleptics have been used up to delivery, observation of neonate for at least 2 days is recommended. In order to prevent neonatal adaptation disorders, prescribers are advised to reduce the dose or even interrupt treatment in the days immediately preceding delivery. Neonates exposed to antipsychotic drugs during the third trimester are at risk of adverse effects including extrapyramidal and withdrawal symptoms such as agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress and feeding problems.
The use of all medication in pregnancy should be avoided whenever possible; particularly in the first trimester. Non-drug treatments should also be considered. When essential, a medication with the best safety record over time should be chosen, employing the lowest effective dose for the shortest possible time. Polypharmacy should be avoided. Teratogens taken in the pre-embryonic period, often quoted as lasting until 14 to 17 days post-conception, are believed to have an all-or-nothing effect. Where drugs have a short half-life, and when the date of conception is certain, this may allow women to be reassured where drug exposure has occurred within this time frame. Further advice may be available from the UK National Teratology Information Service (NTIS) and through ToxBase, available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Prochlorperazine is contraindicated in breastfeeding.
It is suspected that prochlorperazine, in line with other phenothiazines, will appear in breast milk. It cannot be excluded that the nursing infant would be exposed to prochlorperazine. UK licensed product information advises to stop breastfeeding during treatment.
Use of prochlorperazine has been associated with galactorrhoea and hyperprolactinaemia.
Infants of mothers who are breastfeeding while taking psychotropic medication should be monitored for adverse reactions.
Neonates, infants born prematurely, those with low birth weight, those with an unstable gastrointestinal function or who have serious illnesses may require special consideration. For any infant, if a drug is prescribed to the nursing mother, it should be at the lowest practical dose and for the shortest time. When drug administration is unavoidable and breastfeeding is to continue, minimisation of exposure of the infant to the drug may sometimes be achieved by timing the maternal doses to just after a feeding episode. Infants exposed to drugs via breast milk should be monitored for unusual signs or symptoms. Interactions between the drug received by the infant from the mother's milk and medication prescribed for the infant should also be considered, for example, when the drug given to the infant may prevent metabolism of the drug received via breast milk.
Specialist advice is available from the UK Drugs in Lactation Advisory Service at https://www.midlandsmedicines.nhs.uk/content.asp?section=6&subsection=17&pageIdx=1
Decrease in bone mineral density
Deep vein thrombosis (DVT)
Difficulty in micturition
Interference with temperature regulation
Narrow angle glaucoma
Neuroleptic malignant syndrome
Prolongation of QT interval
Purplish pigmentation of cornea, conjunctiva, retina
Purplish pigmentation of skin
Sudden death reported
It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.
The following number will direct the caller to the relevant local centre (0844) 892 0111
Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Last Full Review Date: October 2014
Drugs During Pregnancy and Lactation: Treatment Options and Risk Assessment, 2nd edition (2007) ed. Schaefer, C., Peters, P. and Miller, R. Elsevier, London.
Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk, 9th edition (2011) ed. Briggs, G., Freeman, R. and Yaffe, S. Lippincott Williams & Wilkins, Philadelphia.
Medications and Mothers' Milk, 14th Edition (2010) Hale, T. Hale Publishing, Amarillo, Texas.
The Renal Drug Handbook. 3rd edition. (2009) ed. Ashley, C and Currie, Radcliffe Publishing Ltd, Abingdon.
Summary of Product Characteristics: Prochlorperazine 12.5mg/1ml injection. Antigen International Ltd. Revised December 2011
Summary of Product Characteristics: Stemetil injection. Sanofi-Aventis. Revised August 2014
NICE Evidence Services Available at: www.nice.org.uk Last accessed: 14 September 2017
US National Library of Medicine. Toxicology Data Network. Drugs and Lactation Database (LactMed).
Available at: https://toxnet.nlm.nih.gov
Prochlorperazine Last revised: 7 September, 2013
Last accessed: 14 October, 2014
Already a member? Log in
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content
FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.